Tibotec Prezista Mortality Imbalance Due To Partially Blinded Trials – FDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA officials called the lack of deaths in the control arms of Tibotec’s Prezista trials "striking" and "out of the range of past experience," and attributed the anomaly to the partially blinded study design.